Scientists Have Created the World's Whitest Paint
Want to save big on your air conditioning bills? Wait a few years to coat your home with the world’s whitest paint, which may dramatically reduce or even eliminate the need for air conditioning.
Toxin Transport in Resistant Microbes Revealed at the Molecular Level
Transport proteins have an important role in microbial multi-drug resistance. Scientists have now described the three-dimensional structure of transport protein Pdr5, found also in a similar form in pathogenic fungi. The results could help develop mechanisms to combat dangerous pathogens.
Mike Story Joins Scientific Advisory Board of Protein Discovery
Mike Story joins a distinguished roster of fellow scientists and inventors on Protein Discovery's scientific advisory board.
Metabolon Closes $8 Million Series B Funding Round
These funds will allow Metabolon to make substantial progress toward its commercialization goals.
Lawrence J. Murphy Appointed to Third Wave Board of Directors
Mr. Murphy, 63, brings to Third Wave’s board 30 years of business experience.
Key Heart and Alzheimer's Disease Protein Imaged in Native State
The work focuses on apoE4, one of three specific forms of apolipoprotein E, commonly known as apoE.
Identifying Tumour Gene Signatures with TaqMan®
Applied Biosystems technology has been used to investigate gene expression patterns in cancer.
Fluidigm Announces Former Intel Executive as new CFO
Richard DeLateur has been appointed as Chief Financial Officer.
De Novo Announces Drug Discovery Collaboration with Genzyme
De Novo will apply its molecular structure generating technology to focus on a disease target of interest to Genzyme.
Clinical Data Announces Collaborative Research Agreement with UPCI
Clinical Data will apply metabolomics analysis to serum samples from a population of patients diagnosed with lung cancer.
Caprion Announces Biomarker Discovery Collaboration with ICOS
The agreement in biomarker discovery will use Caprion's CellCarta® proteomics discovery platform.
Alnylam Announces Allowance of U.S. Patent Covering RNAi Therapeutics
Patent rights for Tuschl II are held exclusively by Alnylam for development and commercialization of RNAi therapeutics.